BACKGROUND: In experimental heart failure animal models, remodeling of skeletal and cardiac muscle ryanodine receptors (RyR), including phosphorylation, S-nitrosylation and oxidation, have been reported to contribute to pathologic Ca2+ release, impaired muscle function and fatigue. However, it is not known whether similar remodeling of RyR1 in skeletal muscle occurs in patients with heart failure, and if this is associated with impairment of physical activity. METHODS: We studied 8 sedentary patients with New York Heart Association (NYHA) Class III heart failure and 7 age-matched, healthy, but sedentary controls. All heart failure patients had NYHA Class III and peak VO2, echocardiography and NT-proBNP data consistent with moderate to severe heart failure. The age-matched controls included were allowed hypertension but sub-clinical heart failure was to have been ruled out by normal peak VO2, echocardiography and NT-proBNP. RESULTS: Exercise capacity (VO2max) differed by almost 2-fold between heart failure patients and age-matched controls. Compared with controls, skeletal muscle RyR1 in heart failure patients was excessively phosphorylated, S-nitrosylated and oxidized. Furthermore, RyR1 from heart failure patients was depleted of its stabilizing protein FK 506-binding protein 12 (FKBP12, or calstabin1). CONCLUSIONS: For the first time we show that skeletal muscle RyR1 from human heart failure is post-translationally modified, which corroborates previous data from experimental animal studies. This indicates pathologic Ca2+ release as a potential mechanism behind skeletal muscle weakness and impaired exercise tolerance in patients with heart failure and suggests a potential target for pharmacologic intervention.
BACKGROUND: In experimental heart failure animal models, remodeling of skeletal and cardiac muscle ryanodine receptors (RyR), including phosphorylation, S-nitrosylation and oxidation, have been reported to contribute to pathologic Ca2+ release, impaired muscle function and fatigue. However, it is not known whether similar remodeling of RyR1 in skeletal muscle occurs in patients with heart failure, and if this is associated with impairment of physical activity. METHODS: We studied 8 sedentary patients with New York Heart Association (NYHA) Class III heart failure and 7 age-matched, healthy, but sedentary controls. All heart failurepatients had NYHA Class III and peak VO2, echocardiography and NT-proBNP data consistent with moderate to severe heart failure. The age-matched controls included were allowed hypertension but sub-clinical heart failure was to have been ruled out by normal peak VO2, echocardiography and NT-proBNP. RESULTS: Exercise capacity (VO2max) differed by almost 2-fold between heart failurepatients and age-matched controls. Compared with controls, skeletal muscle RyR1 in heart failurepatients was excessively phosphorylated, S-nitrosylated and oxidized. Furthermore, RyR1 from heart failurepatients was depleted of its stabilizing protein FK 506-binding protein 12 (FKBP12, or calstabin1). CONCLUSIONS: For the first time we show that skeletal muscle RyR1 from humanheart failure is post-translationally modified, which corroborates previous data from experimental animal studies. This indicates pathologic Ca2+ release as a potential mechanism behind skeletal muscle weakness and impaired exercise tolerance in patients with heart failure and suggests a potential target for pharmacologic intervention.
Authors: Daniel C Andersson; Matthew J Betzenhauser; Steven Reiken; Albano C Meli; Alisa Umanskaya; Wenjun Xie; Takayuki Shiomi; Ran Zalk; Alain Lacampagne; Andrew R Marks Journal: Cell Metab Date: 2011-08-03 Impact factor: 27.287
Authors: Xander H T Wehrens; Stephan E Lehnart; Steven Reiken; Roel van der Nagel; Raymond Morales; Jie Sun; Zhenzhuang Cheng; Shi-Xiang Deng; Leon J de Windt; Donald W Landry; Andrew R Marks Journal: Proc Natl Acad Sci U S A Date: 2005-06-22 Impact factor: 11.205
Authors: Andrew M Bellinger; Steven Reiken; Christian Carlson; Marco Mongillo; Xiaoping Liu; Lisa Rothman; Stefan Matecki; Alain Lacampagne; Andrew R Marks Journal: Nat Med Date: 2009-02-08 Impact factor: 53.440
Authors: Steven Reiken; Xander H T Wehrens; John A Vest; Alessandro Barbone; Stefan Klotz; Donna Mancini; Daniel Burkhoff; Andrew R Marks Journal: Circulation Date: 2003-05-12 Impact factor: 29.690
Authors: Daniel C Andersson; Matthew J Betzenhauser; Steven Reiken; Alisa Umanskaya; Takayuki Shiomi; Andrew R Marks Journal: J Physiol Date: 2012-10-15 Impact factor: 5.182
Authors: Andrew R Coggan; Joshua L Leibowitz; Catherine Anderson Spearie; Ana Kadkhodayan; Deepak P Thomas; Sujata Ramamurthy; Kiran Mahmood; Soo Park; Suzanne Waller; Marsha Farmer; Linda R Peterson Journal: Circ Heart Fail Date: 2015-07-15 Impact factor: 8.790
Authors: Marine Bacchi; Magali Jullian; Serena Sirigu; Benjamin Fould; Tiphaine Huet; Lisa Bruyand; Mathias Antoine; Laurent Vuillard; Luisa Ronga; Leonard M G Chavas; Olivier Nosjean; Gilles Ferry; Karine Puget; Jean A Boutin Journal: Protein Sci Date: 2016-10-13 Impact factor: 6.725
Authors: Alexander Kushnir; Gaetano Santulli; Steven R Reiken; Ellie Coromilas; Sarah J Godfrey; Danielle L Brunjes; Paolo C Colombo; Melana Yuzefpolskaya; Seth I Sokol; Richard N Kitsis; Andrew R Marks Journal: Circulation Date: 2018-09-11 Impact factor: 29.690
Authors: Vinaya Mulkareddy; Susan B Racette; Andrew R Coggan; Linda R Peterson Journal: Biochim Biophys Acta Mol Basis Dis Date: 2018-09-24 Impact factor: 5.187
Authors: Marino DiFranco; Marbella Quiñonez; Perry Shieh; Gregg C Fonarow; Daniel Cruz; Mario C Deng; Julio L Vergara; Holly R Middlekauff Journal: PLoS One Date: 2014-10-13 Impact factor: 3.240
Authors: Kristen E Boyle; Hyonson Hwang; Rachel C Janssen; James M DeVente; Linda A Barbour; Teri L Hernandez; Lawrence J Mandarino; Martha Lappas; Jacob E Friedman Journal: PLoS One Date: 2014-09-12 Impact factor: 3.240